Cargando…
Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values
Aspergillosis is an invasive fungal disease associated with high mortality. Antifungal susceptibility testing (AFST) is receiving increasing consideration for managing patients, as well as for surveilling emerging drug resistance, despite having time-consuming and technically complex reference metho...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607534/ https://www.ncbi.nlm.nih.gov/pubmed/36297597 http://dx.doi.org/10.3390/pharmaceutics14102161 |
_version_ | 1784818569160163328 |
---|---|
author | Melhem, Marcia S. C. Coelho, Vivian C. Fonseca, Claudia A. de Oliveira, Lidiane Bonfietti, Lucas X. Szeszs, Maria. W. Magri, Marcello M. C. Dorneles, Francine S. Taguchi, Hideaki Moreira, Daniel V. S. Motta, Adriana L. Batista, Marjorie V. Kamei, Katsuhiko Shikanai-Yasuda, Maria A. |
author_facet | Melhem, Marcia S. C. Coelho, Vivian C. Fonseca, Claudia A. de Oliveira, Lidiane Bonfietti, Lucas X. Szeszs, Maria. W. Magri, Marcello M. C. Dorneles, Francine S. Taguchi, Hideaki Moreira, Daniel V. S. Motta, Adriana L. Batista, Marjorie V. Kamei, Katsuhiko Shikanai-Yasuda, Maria A. |
author_sort | Melhem, Marcia S. C. |
collection | PubMed |
description | Aspergillosis is an invasive fungal disease associated with high mortality. Antifungal susceptibility testing (AFST) is receiving increasing consideration for managing patients, as well as for surveilling emerging drug resistance, despite having time-consuming and technically complex reference methodologies. The Sensititre YeastOne (SYO) and Etest methods are widely utilized for yeasts but have not been extensively evaluated for Aspergillus isolates. We obtained Posaconazole (POS), Voriconazole (VCZ), Itraconazole (ITC), Amphotericin B (AMB), Caspofungin (CAS), and Anidulafungin (AND) minimum inhibitory concentrations (MICs) for both the Etest (n = 330) and SYO (n = 339) methods for 106 sequenced clinical strains. For 84 A. fumigatus, we analyzed the performance of both commercial methods in comparison with the CLSI-AFST, using available cutoff values. An excellent correlation could be demonstrated for Etest-AMB and Etest-VCZ (p < 0.01). SYO-MICs of AMB, VCZ, and POS resulted in excellent essential agreement (>93%), and >80% for AMB, VCZ, and ITC Etest-MICs. High categoric agreement was found for AMB, ITC, and CAS Etest-MICs (>85%) and AMB SYO-MICs (>90%). The considerable number of major/very major errors found using Etest and SYO, possibly related to the proposed cutoffs and associated with the less time-consuming processes, support the need for the improvement of commercial methods for Aspergillus strains. |
format | Online Article Text |
id | pubmed-9607534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96075342022-10-28 Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values Melhem, Marcia S. C. Coelho, Vivian C. Fonseca, Claudia A. de Oliveira, Lidiane Bonfietti, Lucas X. Szeszs, Maria. W. Magri, Marcello M. C. Dorneles, Francine S. Taguchi, Hideaki Moreira, Daniel V. S. Motta, Adriana L. Batista, Marjorie V. Kamei, Katsuhiko Shikanai-Yasuda, Maria A. Pharmaceutics Article Aspergillosis is an invasive fungal disease associated with high mortality. Antifungal susceptibility testing (AFST) is receiving increasing consideration for managing patients, as well as for surveilling emerging drug resistance, despite having time-consuming and technically complex reference methodologies. The Sensititre YeastOne (SYO) and Etest methods are widely utilized for yeasts but have not been extensively evaluated for Aspergillus isolates. We obtained Posaconazole (POS), Voriconazole (VCZ), Itraconazole (ITC), Amphotericin B (AMB), Caspofungin (CAS), and Anidulafungin (AND) minimum inhibitory concentrations (MICs) for both the Etest (n = 330) and SYO (n = 339) methods for 106 sequenced clinical strains. For 84 A. fumigatus, we analyzed the performance of both commercial methods in comparison with the CLSI-AFST, using available cutoff values. An excellent correlation could be demonstrated for Etest-AMB and Etest-VCZ (p < 0.01). SYO-MICs of AMB, VCZ, and POS resulted in excellent essential agreement (>93%), and >80% for AMB, VCZ, and ITC Etest-MICs. High categoric agreement was found for AMB, ITC, and CAS Etest-MICs (>85%) and AMB SYO-MICs (>90%). The considerable number of major/very major errors found using Etest and SYO, possibly related to the proposed cutoffs and associated with the less time-consuming processes, support the need for the improvement of commercial methods for Aspergillus strains. MDPI 2022-10-11 /pmc/articles/PMC9607534/ /pubmed/36297597 http://dx.doi.org/10.3390/pharmaceutics14102161 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Melhem, Marcia S. C. Coelho, Vivian C. Fonseca, Claudia A. de Oliveira, Lidiane Bonfietti, Lucas X. Szeszs, Maria. W. Magri, Marcello M. C. Dorneles, Francine S. Taguchi, Hideaki Moreira, Daniel V. S. Motta, Adriana L. Batista, Marjorie V. Kamei, Katsuhiko Shikanai-Yasuda, Maria A. Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values |
title | Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus
fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values |
title_full | Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus
fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values |
title_fullStr | Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus
fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values |
title_full_unstemmed | Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus
fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values |
title_short | Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus
fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values |
title_sort | evaluation of the sensititre yeastone and etest in comparison with clsi m38-a2 for antifungal susceptibility testing of three azoles, amphotericin b, caspofungin, and anidulafungin, against aspergillus
fumigatus and other species, using new clinical breakpoints and epidemiological cutoff values |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607534/ https://www.ncbi.nlm.nih.gov/pubmed/36297597 http://dx.doi.org/10.3390/pharmaceutics14102161 |
work_keys_str_mv | AT melhemmarciasc evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues AT coelhovivianc evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues AT fonsecaclaudiaa evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues AT deoliveiralidiane evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues AT bonfiettilucasx evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues AT szeszsmariaw evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues AT magrimarcellomc evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues AT dornelesfrancines evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues AT taguchihideaki evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues AT moreiradanielvs evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues AT mottaadrianal evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues AT batistamarjoriev evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues AT kameikatsuhiko evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues AT shikanaiyasudamariaa evaluationofthesensititreyeastoneandetestincomparisonwithclsim38a2forantifungalsusceptibilitytestingofthreeazolesamphotericinbcaspofunginandanidulafunginagainstaspergillusfumigatusandotherspeciesusingnewclinicalbreakpointsandepidemiologicalcutoffvalues |